Monoclonal antibodies and Fc fragments for treating solid tumors

Abstract

Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use of monoclonal antibodies and Fc fragments in various fields in medicine. In this context, a rapidly growing number of these substances have also emerged in the field of oncology. This review will summarize the currently approved monoclonal antibodies used for the treatment of solid tumors with a focus on their clinical application, biological background, and currently ongoing trials.

Keywords:

• targeted therapy
• monoclonal antibodies
• cancer
• biological therapy

Disclosure

The authors report no conflicts of interest in this work.